Trading at 12 times 2005 earnings, shares are reflecting a seemingly bearish view of Pfizer's growth prospects, in our opinion. With these low expectations built into the shares, we are encouraged that Pfizer's $4 billion cost restructuring will stabilize near-term earnings.
-Chris Schott
Select a background
More quotes by Chris Schott
Popular Authors
A curated listing of popular authors.